• Jerry C. Jacobs
Part of the Comprehensive Manuals in Pediatrics book series (CM PEDIATRICS)


The hallmark of the heterogeneous but related group of disorders called scleroderma is an area of hard, tight, inelastic (hide-bound) skin and subcutaneous tissue (Fig. 8.1).1,2 Fewer than 100 affected children have been reported on in the more than 130 years since the disorder was first described. The paucity of case reports does not reflect great rarity; one pediatric rheumatology clinic alone has reported 48 cases.3 It does reflect physician frustration: this disorder has been difficult to categorize; pathogenesis has defied understanding; treatment has been unsatisfactory.


Systemic Sclerosis Progressive Systemic Sclerosis Porphyria Cutanea Tarda Scleroderma Renal Crisis Esophageal Dysmotility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    LeRoy EC: Scleroderma (systemic sclerosis). In: Kelly WN, Harris ED Jr, Ruddy S et al. (eds.) Textbook of Rheumatology. Saunders, Philadelphia, 1981, pp. 12111230.Google Scholar
  2. 2.
    Masi AT, Rodnan GP, Medsger TA, et al.: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Bull Rheum Dis 31:1–6, 1981; Arthritis Rheum 23: 581–590, 1980.Google Scholar
  3. 3.
    Kornreich HK, King KK, Bernstein, BH, et al.: Scleroderma in childhood. Arthritis Rheum 20: 343–350, 1977.PubMedGoogle Scholar
  4. 4.
    Cassidy JT, Sullivan DB, Dabich L, et al.: Scleroderma in children. Arthritis Rheum 20: 351–354 1977.PubMedGoogle Scholar
  5. 5.
    Ackerman AB: Histologic Diagnosis of Inflammatory Skin Diseases. Lea and Febiger, Philadelphia, 1978.Google Scholar
  6. 6.
    Rodnan GP: Progressive systemic sclerosis (scleroderma). In: McCarty DJ (ed.) Arthritis and Allied Conditions, 9th ed. Lea and Febiger, Philadelphia, 1979, pp. 762–809.Google Scholar
  7. 7.
    Tan EM, Rodnan GP, Garcia I, et al.: Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 23: 617–625, 1980.PubMedCrossRefGoogle Scholar
  8. 8.
    Postlethwaite EE, Synderman R, Kang AH: The chemotactic attraction of human fibroblasts to a lymphocyte-derived factor. J Exper Med 144: 1188–1203, 1976.CrossRefGoogle Scholar
  9. 9.
    LeRoy EC: Increased collagen synthesis by scleroderma skin fibroblasts in vitro: A possible defect in the regulation of the scleroderma fibroblast. J. Clin Invest 54: 880889, 1974.Google Scholar
  10. 10.
    Kahaleh MB, Sherber GK, LeRoy EC: Endothelial injury in scleroderma. J Exp Med 149: 1326–1335, 1979.PubMedCrossRefGoogle Scholar
  11. 11.
    Gray RG, Altman RD: Progressive systemic sclerosis in a family. Arthritis Rheum 20: 35–41, 1977.PubMedCrossRefGoogle Scholar
  12. 12.
    Braverman IM: Skin Signs of Systemic Disease. Saunders, Philadelphia, 1970. 13 LeRoy EC, Downey JA, Cannon PJ: Skin capillary blood flow in scleroderma. J Clin Invest 50: 930–939, 1971.CrossRefGoogle Scholar
  13. 14.
    West SG, Killian PJ, Lawless OJ: Association of myositis and myocarditis in progressive systemic sclerosis. Arthritis Rheum 24: 662–667, 1981.PubMedCrossRefGoogle Scholar
  14. 15.
    Smith JW, Clements PJ, Levisman J, et al.: Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies. Am J Med 66: 28–33, 1979.PubMedCrossRefGoogle Scholar
  15. 16.
    Cannon PJ: Medical management of renal scleroderma. N Engl J Med 299: 886887, 1978.Google Scholar
  16. 17.
    Cannon PJ, Hassar, M, Case DB, et al.: The relationship of hypertension and renal failure in scleroderma (PSS) to structural and functional abnormalities of the renal cortical circulation. Medicine 53: 1–46, 1974.PubMedCrossRefGoogle Scholar
  17. 17A.
    Schulze-Delrieu K: Metoclopramide. Gastroenterology 77: 768–779, 1979.Google Scholar
  18. 18.
    Thanik KD, Chey WY, Shah AN, et al.: Reflux esophagitis: Effects of oral bethanechol on symptoms and endoscopic findings. Ann Intern Med 93: 805–808, 1980.PubMedGoogle Scholar
  19. 18A.
    Franks AG Jr.: Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1: 76–77, 1982.PubMedCrossRefGoogle Scholar
  20. 19.
    Romeo SG, Whalen RE, Tindall JP: Intra-arterial administration of reserpine; its use in patients with Raynaud’s disease or Raynaud’s phenomenon. Arch Intern Med 125: 825–829, 1970.PubMedCrossRefGoogle Scholar
  21. 20.
    O’Reilly MJG, Talpos G, Roberts VC, et al.: Controlled trial of plasma exchange in treatment of Raynaud’s syndrome. Br Med J 1: 1113–1115, 1979.PubMedCrossRefGoogle Scholar
  22. 21.
    Gordon RS (ed.): From the NIH: Research findings of potential value to the practitioner: Biofeedback for patients with Raynaud’s phenomenon. JAMA 242:509510, 1979.Google Scholar
  23. 22.
    Lopez-Ovejero JA, Saal SD, D’Angelo WA, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 300: 1417–1419, 1979.PubMedCrossRefGoogle Scholar
  24. 23.
    Mitnick PD, Feig PU: Control of hypertension and reversal of vascular and renal failure in scleroderma. N Engl J Med 299: 871–872, 1978.PubMedCrossRefGoogle Scholar
  25. 24.
    Wasner, C, Cooke CR, Fries JF: Successful medical treatment of scleroderma renal crisis. N Engl J Med 299: 873–875, 1978.PubMedCrossRefGoogle Scholar
  26. 25.
    Moynahan EJ: Penicillamine in the treatment of morphea and keloid in children. Postgrad Med J 50 (Suppl. 2): 39–40, 1974.PubMedGoogle Scholar
  27. 26.
    Rodnan GP: Progressive systemic sclerosis and penicillamine. J Rheum [Suppl.] 7: 116–120, 1981.Google Scholar
  28. 27.
    Rodnan GP: When is scleroderma not scleroderma: The differential diagnosis of progressive systemic sclerosis. Bull Rheum Dis 31: 7–10, 1981.PubMedGoogle Scholar
  29. 28.
    Greenberg LM, Geppert C, Worthen HG, et al.: Scleredema “adultorum” in children. Pediatrics 32: 1044–1054, 1963.PubMedGoogle Scholar
  30. 29.
    Yogman M, Echeverria P: Scleredema and carditis: Report of a case and review of the literature. Pediatrics 54: 108–110, 1974.PubMedGoogle Scholar
  31. 30.
    Laymon CW, Peterson WC Jr: Lipogranulomatosis subcutanea (RothmannMakai). Arch Dermatol 90: 288–292, 1964.PubMedCrossRefGoogle Scholar
  32. 31.
    Shulman LE: Diffuse fasciitis with eosinophilia: A new syndrome? Trans Assoc Am Physicians 88: 70–86, 1975.PubMedGoogle Scholar
  33. 32.
    Hoffman R, Dainiak N, Sibrack L, et al.: Antibody-mediated aplastic anemia and diffuse fasciitis. N Engl J Med 300: 718–721, 1979.PubMedCrossRefGoogle Scholar
  34. 33.
    Britt WJ, Duray PH, Dahl MV, et al.: Diffuse fasciitis with eosinophilia: A steroid-responsive variant of scleroderma. J Pediatr 97: 432–434, 1980.PubMedCrossRefGoogle Scholar
  35. 34.
    Kent LT, Cramer SF, Moskowitz RW: Eosinophilic fasciitis. Arthritis Rheum 24: 677–683, 1981.PubMedCrossRefGoogle Scholar
  36. 35.
    Ansell BM, Nasseh GA, Bywaters, EGL: Scleroderma in childhood. Ann Rheum Dis 35: 189–197, 1976.PubMedCrossRefGoogle Scholar
  37. 36.
    Hoefnagel D, Jalbert EO, Publow DG, et al.: Progressive fibrosis of the deltoid muscles. J Pediatr 92: 79–81, 1978.PubMedCrossRefGoogle Scholar
  38. 37.
    Sternberg, EM, VanWoert MH, Young SN, et al.: Development of a sclerodermalike illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 303: 782–787, 1980.PubMedCrossRefGoogle Scholar
  39. 38.
    Shulman HM, Sale GE, Lerner KG, et al.: Chronic graft-versus-host disease in man. Am J Pathol 91: 545–570, 1978.PubMedGoogle Scholar
  40. 39.
    Kumagai Y, Abe C, Shiokawa Y: Scleroderma after cosmetic surgery. Arthritis Rheum 22: 532–537, 1979.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1982

Authors and Affiliations

  • Jerry C. Jacobs
    • 1
  1. 1.Section of Pediatric Rheumatology Department of Pediatrics College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations